{"id":2637,"date":"2025-10-05T17:58:17","date_gmt":"2025-10-05T14:28:17","guid":{"rendered":"https:\/\/kiacell-immune.com\/clinical-trial\/"},"modified":"2025-11-24T18:04:14","modified_gmt":"2025-11-24T14:34:14","slug":"clinical-trial","status":"publish","type":"page","link":"https:\/\/kiacell-immune.com\/fa\/clinical-trial\/","title":{"rendered":"\u06a9\u0627\u0631\u0622\u0632\u0645\u0627\u06cc\u06cc \u0628\u0627\u0644\u06cc\u0646\u06cc"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"2637\" class=\"elementor elementor-2637 elementor-2307\" data-elementor-post-type=\"page\">\n\t\t\t\t<div class=\"elementor-element elementor-element-5d1c13a e-con-full e-flex e-con e-parent\" data-id=\"5d1c13a\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-8813955 elementor-widget elementor-widget-heading\" data-id=\"8813955\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">\u06a9\u0627\u0631\u0622\u0632\u0645\u0627\u06cc\u06cc \u0628\u0627\u0644\u06cc\u0646\u06cc<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-76344ae e-flex e-con-boxed e-con e-parent\" data-id=\"76344ae\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-3b1a7dd elementor-widget elementor-widget-html\" data-id=\"3b1a7dd\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t\t<!-- Clinical Trials \u2013 final (Phase fix, bright header) -->\r\n<div class=\"clinical-table\" dir=\"ltr\">\r\n  <div class=\"ct-table-wrap\" role=\"region\" aria-label=\"Clinical Trials Table\" tabindex=\"0\">\r\n    <table class=\"ct-table\" id=\"ctTable\">\r\n      <thead>\r\n        <tr>\r\n          <th>Therapy<\/th>\r\n          <th>Indication<\/th>\r\n          <th>Sites<\/th>\r\n          <th>Status<\/th>\r\n          <th>NCT#<\/th>\r\n          <th>Trial Name<\/th>\r\n          <th>IRCT<\/th>\r\n        <\/tr>\r\n      <\/thead>\r\n      <tbody>\r\n        <tr>\r\n          <td data-label=\"Therapy\">NK Cell Therapy<\/td>\r\n          <td data-label=\"Indication\">Glioma, Glioblastoma Multiforme, High Grade Glioma (III or IV)<\/td>\r\n          <td data-label=\"Sites\">Rasoul Akram Hospital, Tehran, Iran<\/td>\r\n          <td data-label=\"Status\"><span class=\"pill recruiting\">Recruiting&nbsp;<span class=\"phase\">Phase II<\/span><\/span><\/td>\r\n          <td data-label=\"NCT#\"><a class=\"link\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT06687681\" target=\"_blank\" rel=\"noopener\">NCT06687681<\/a><\/td>\r\n          <td data-label=\"Trial Name\">Injection of Active Allogeneic Natural Killer Cells in Patients with Gliomas<\/td>\r\n          <td data-label=\"IRCT\">IR.ACECR.ROYAN.REC.1402.001<br>IRCT20170122032121N7<\/td>\r\n        <\/tr>\r\n        <tr>\r\n          <td data-label=\"Therapy\">NK Cell Therapy<\/td>\r\n          <td data-label=\"Indication\">Recurrent, Refractory Neuroblastoma<\/td>\r\n          <td data-label=\"Sites\">Rasoul Akram Hospital, Tehran, Iran<\/td>\r\n          <td data-label=\"Status\"><span class=\"pill recruiting\">Recruiting&nbsp;<span class=\"phase\">Phase I<\/span><\/span><\/td>\r\n          <td data-label=\"NCT#\"><a class=\"link\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT06674265\" target=\"_blank\" rel=\"noopener\">NCT06674265<\/a><\/td>\r\n          <td data-label=\"Trial Name\">Safety and Efficacy of Systemic Allogeneic NK Cells in Refractory\/Recurrent High-risk Neuroblastoma<\/td>\r\n          <td data-label=\"IRCT\">IR.ACECR.ROYAN.REC.1403.032<br>IRCT20170122032121N8<\/td>\r\n        <\/tr>\r\n        <tr>\r\n          <td data-label=\"Therapy\">NK Cell Therapy<\/td>\r\n          <td data-label=\"Indication\">Recurrent Glioblastoma Multiforme Patients<\/td>\r\n          <td data-label=\"Sites\">Royan Institute, Tehran, Iran<\/td>\r\n          <td data-label=\"Status\"><span class=\"pill completed\">Completed&nbsp;<span class=\"phase\">Phase I<\/span><\/span><\/td>\r\n          <td data-label=\"NCT#\"><span class=\"badge muted\">Pending<\/span><\/td>\r\n          <td data-label=\"Trial Name\">NK Cell Therapy for Recurrent Glioblastoma Multiforme Patients<\/td>\r\n          <td data-label=\"IRCT\">IR.ACECR.ROYAN.REC.1400.077<br>IRCT20170122032121N6<\/td>\r\n        <\/tr>\r\n        <tr>\r\n          <td data-label=\"Therapy\">NK Cell Therapy<\/td>\r\n          <td data-label=\"Indication\">Recurrent malignant brain tumors<\/td>\r\n          <td data-label=\"Sites\">Children\u2019s Medical Center Hospital, Tehran, Iran<\/td>\r\n          <td data-label=\"Status\"><span class=\"pill completed\">Completed&nbsp;<span class=\"phase\">Phase I<\/span><\/span><\/td>\r\n          <td data-label=\"NCT#\"><a class=\"link\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT05108012\" target=\"_blank\" rel=\"noopener\">NCT05108012<\/a><\/td>\r\n          <td data-label=\"Trial Name\">Intra-lesion Injection of Activated Natural Killer (NK) Cells in Recurrent Malignant Brain Tumors<\/td>\r\n          <td data-label=\"IRCT\">IR.ACECR.ROYAN.REC.1398.261<br>IRCT20170122032121N5<\/td>\r\n        <\/tr>\r\n      <\/tbody>\r\n    <\/table>\r\n  <\/div>\r\n<\/div>\r\n\r\n<style>\r\n.clinical-table{\r\n  --g1:#48a74e;--g2:#73ba77;--ink:#202425;--border:#e6ece7;--bg:#fff;\r\n  font-family:system-ui,-apple-system,\"Segoe UI\",Roboto,Arial,sans-serif;\r\n  color:var(--ink)\r\n}\r\n.ct-table-wrap{border:1px solid var(--border);border-radius:18px;overflow:hidden;background:var(--bg);\r\n  box-shadow:0 10px 24px rgba(72,167,78,.12),0 3px 12px rgba(0,0,0,.05)}\r\n.ct-table{width:100%;border-collapse:separate;border-spacing:0}\r\n.ct-table thead th{\r\n  position:sticky;top:0;z-index:1;padding:1rem .9rem;text-align:left;font-weight:800;\r\n  color:#06330f;background:linear-gradient(90deg,var(--g1),var(--g2));border-bottom:2px solid rgba(72,167,78,.25)\r\n}\r\n.ct-table tbody td{padding:.85rem .9rem;vertical-align:top;border-bottom:1px solid var(--border);background:#fff}\r\n.ct-table tbody tr:nth-child(odd) td{background:#fbfffb}\r\n.ct-table tbody tr:hover td{background:#f3fbf4}\r\n.ct-table tbody td+td{box-shadow:inset 1px 0 0 rgba(72,167,78,.07)}\r\n\r\n.pill{\r\n  display:inline-flex;align-items:center;gap:.35rem;padding:.26rem .6rem;border-radius:999px;\r\n  font-size:.8rem;font-weight:700;border:1px solid rgba(72,167,78,.3);\r\n  background:linear-gradient(180deg,#eaffef,#dff7e5);color:#0b3b17;\r\n  white-space:nowrap;max-width:100%;box-sizing:border-box\r\n}\r\n.pill.completed{background:linear-gradient(180deg,#eef3ef,#e6ece7);color:#2b3130;border-color:#d5dbd1}\r\n.pill .phase{\r\n  background:#fff;color:#0d3a15;padding:.08rem .4rem;border-radius:999px;\r\n  border:1px solid rgba(72,167,78,.25);font-size:.72rem;font-weight:800;\r\n  white-space:nowrap;flex:0 0 auto\r\n}\r\n.badge.muted{display:inline-block;padding:.24rem .5rem;border-radius:8px;font-size:.76rem;\r\n  font-weight:700;background:#f1f3f2;color:#606665;border:1px solid #e1e5e3;white-space:nowrap}\r\n.link{color:#2c9c34;font-weight:700;text-decoration:none}\r\n.link:hover{color:#48a74e;text-decoration:underline}\r\n\r\n\/* ===== Responsive cards (show all fields) ===== *\/\r\n@media(max-width:980px){\r\n  .ct-table thead{display:none}\r\n  .ct-table,.ct-table tbody,.ct-table tr,.ct-table td{display:block;width:100%}\r\n  .ct-table tbody tr{\r\n    margin:.9rem 0;border:1px solid var(--border);border-radius:16px;\r\n    box-shadow:0 10px 20px rgba(72,167,78,.1);\r\n    background:#fff;display:grid;grid-template-columns:minmax(150px,1fr) 1fr;gap:.25rem 1rem;\r\n    padding:.6rem\r\n  }\r\n  .ct-table tbody td{border:none;background:transparent;padding:.45rem .55rem;\r\n    display:flex;flex-direction:column;gap:.25rem;min-width:0;overflow:visible}\r\n  .ct-table tbody td::before{\r\n    content:attr(data-label);font-size:.78rem;font-weight:800;color:#0f3a15;margin-bottom:.05rem\r\n  }\r\n  .ct-table tbody td[data-label=\"Trial Name\"]{grid-column:1\/-1;font-weight:800;line-height:1.4;\r\n    padding-top:.7rem;background:linear-gradient(90deg,rgba(72,167,78,.06),rgba(115,186,119,.06));\r\n    border-radius:10px}\r\n  \/* status full width + badge fix *\/\r\n  .ct-table tbody td[data-label=\"Status\"]{grid-column:1\/-1}\r\n  .pill{font-size:.74rem;padding:.2rem .46rem;gap:.28rem;max-width:100%;\r\n    display:inline-flex;align-items:center;white-space:nowrap;overflow:hidden;text-overflow:clip}\r\n  .pill .phase{font-size:.66rem;padding:.04rem .32rem;white-space:nowrap;flex:0 0 auto}\r\n}\r\n<\/style>\r\n\r\n<script>\r\n(function(){\r\n  const table=document.getElementById('ctTable');\r\n  if(!table)return;\r\n  const isCompact=()=>window.matchMedia('(max-width:980px)').matches;\r\n  table.querySelectorAll('thead th').forEach((th,idx)=>{\r\n    th.style.cursor='pointer';\r\n    th.addEventListener('click',()=>{\r\n      if(isCompact())return;\r\n      const tbody=table.tBodies[0];\r\n      const rows=Array.from(tbody.querySelectorAll('tr'));\r\n      const asc=th.dataset.sortAsc!=='true';\r\n      th.dataset.sortAsc=String(asc);\r\n      rows.sort((a,b)=>{\r\n        const A=(a.cells[idx]?.innerText||'').trim().toLowerCase();\r\n        const B=(b.cells[idx]?.innerText||'').trim().toLowerCase();\r\n        const nA=parseFloat(A.replace(\/[^\\d.]\/g,'')),nB=parseFloat(B.replace(\/[^\\d.]\/g,''));\r\n        const num=!isNaN(nA)&&!isNaN(nB)&&( \/\\d\/.test(A)||\/\\d\/.test(B) );\r\n        if(num)return asc?(nA-nB):(nB-nA);\r\n        return asc?A.localeCompare(B):B.localeCompare(A);\r\n      });\r\n      rows.forEach(r=>tbody.appendChild(r));\r\n    });\r\n  });\r\n})();\r\n<\/script>\r\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>\u06a9\u0627\u0631\u0622\u0632\u0645\u0627\u06cc\u06cc \u0628\u0627\u0644\u06cc\u0646\u06cc Therapy Indication Sites Status NCT# Trial Name IRCT NK Cell Therapy Glioma, Glioblastoma Multiforme, High Grade Glioma (III or IV) Rasoul Akram Hospital, Tehran, Iran Recruiting&nbsp;Phase II NCT06687681 Injection of Active Allogeneic Natural Killer Cells in Patients with Gliomas IR.ACECR.ROYAN.REC.1402.001IRCT20170122032121N7 NK Cell Therapy Recurrent, Refractory Neuroblastoma Rasoul Akram Hospital, Tehran, Iran Recruiting&nbsp;Phase I [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"class_list":["post-2637","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/kiacell-immune.com\/fa\/wp-json\/wp\/v2\/pages\/2637","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kiacell-immune.com\/fa\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/kiacell-immune.com\/fa\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/kiacell-immune.com\/fa\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kiacell-immune.com\/fa\/wp-json\/wp\/v2\/comments?post=2637"}],"version-history":[{"count":4,"href":"https:\/\/kiacell-immune.com\/fa\/wp-json\/wp\/v2\/pages\/2637\/revisions"}],"predecessor-version":[{"id":2643,"href":"https:\/\/kiacell-immune.com\/fa\/wp-json\/wp\/v2\/pages\/2637\/revisions\/2643"}],"wp:attachment":[{"href":"https:\/\/kiacell-immune.com\/fa\/wp-json\/wp\/v2\/media?parent=2637"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}